Caricamento quotazioni...
Previsioni
| Acquista |
0 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
ABVC BioPharma confirms directors and expands equity participation plan
ABVC BioPharma shareholders approved all proposals at the annual general meeting, including the re-election of 11 directors and the appointment of Simon & Edward, LLP as the independent auditor for 2026. At the same time, the amended and restated equity participation plan was expanded: shares equal to 15% of the issued common stock at the time of the meeting are now reserved, with an automatic annual increase of 5% of outstanding shares starting 1 January 2027. The company has a market capitalization of USD 26.19 million; the stock is down roughly 50% year-to-date. » Altro su de.investing.com
ABVC BioPharma ties management incentive plan to $1 billion market capitalization
The board of directors of ABVC BioPharma has approved a performance-based incentive plan for directors and executives that will only take effect if the company reaches a $1 billion market capitalization for 30 consecutive trading days by December 31, 2027. If met, common shares equal to 1% of outstanding shares will be granted, subject to a total cap of $10 million and a maximum of $1 million per recipient. Grants will be made under the existing Equity Incentive Plan and are contingent on milestones defined in the plan as well as approval by the compensation committee and the board. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -645,71K | 66,28% |
| EBITDA | -662,29K | 62,81% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 19,05 Mln € |
Numero di azioni | 26 Mln |
Massimo/minimo a 52 settimane | 2,93 € - 0,61 € |
| Dividendi | No |
Beta | 0,54 |
Rapporto P/E | -2,88 |
Rapporto PEG | 0,04 |
Rapporto P/B | 2,15 |
Rapporto P/S | -27,76 |
Profilo aziendale
ABVC BioPharma, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt Medikamente und medizinische Geräte, um ungedeckte medizinische Bedürfnisse in den Vereinigten Staaten zu erfüllen. Das Unternehmen entwickelt ABV-1501, ein Kombinationspräparat zur Behandlung von dreifach negativem Brustkrebs, das sich in der klinischen Phase I/II befindet; ABV-1504 hat die klinische Phase II zur Behandlung von schweren depressiven Störungen abgeschlossen; ABV-1505 befindet sich in der klinischen Phase II zur Behandlung der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung; ABV-1703 hat klinische Studien der Phase I zur Behandlung von Bauchspeicheldrüsenkrebs abgeschlossen; ABV-1702 hat klinische Studien der Phase I zur Behandlung von myelodysplastischen Syndromen abgeschlossen; ABV-1601 befindet sich in klinischen Studien der Phase I/II zur Behandlung von Depressionen bei Krebspatienten; und ABV-1701 Vitargus zur Behandlung von Netzhautablösungen oder Glaskörperblutungen. Das Unternehmen hat eine gemeinsame Entwicklungsvereinbarung mit der Rgene Corporation sowie Kooperationsvereinbarungen mit der BioHopeKing Corporation und der BioFirst Corporation. Das Unternehmen hat seinen Sitz in Fremont, Kalifornien. ABVC BioPharma, Inc. ist eine Tochtergesellschaft der YuanGene Corporation.
| Nome | ABVC BioPharma |
| CEO | Uttam Yashwant Patil |
| Sede centrale | Fremont,
ca Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 10/11/2004 |
| Dipendenti | 18 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | ABVC |
Scopri gli asset
Gli azionisti di ABVC BioPharma investono anche nei seguenti asset
